Abstract
Chronic myelogenous leukemia (CML) accounts for 15% of adult leukemias. In 2007, an estimated 4500 cases will be diagnosed and 900 patients will die of the disease. The goal of CML therapy is complete remission, which typically progresses from hematologic to cytogenetic remission. These updated 2007 guidelines include changes to several treatment recommendations, including considerations for imatinib dosing, the use of interferon, and management of dasatinib toxicity. Recommendations for hematopoetic stem cell transplantation have also been updated.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 474-496 |
| Number of pages | 23 |
| Journal | JNCCN Journal of the National Comprehensive Cancer Network |
| Volume | 5 |
| Issue number | 5 |
| State | Published - May 1 2007 |
Fingerprint
Keywords
- Chronic myelogenous leukemia
- Desatinib
- Imatinib
- Karyotyping
- NCCN clinical practice guidelines
- Polymerase chain reaction
- Transplantation
ASJC Scopus subject areas
- Oncology
Cite this
Chronic myelogenous leukemia. / O'Brien, Susan; Berman, Ellin; Bhalla, Kapil; Copelan, Edward A.; DeVetten, Marcel P; Emanuel, Peter D.; Erba, Harry P.; Greenberg, Peter L.; Moore, Joseph O.; Przepiorka, Donna; Radich, Jerald P.; Schilder, Russell J.; Shami, Paul; Smith, B. Douglas; Snyder, David S.; Soiffer, Robert J.; Tallman, Martin S.; Talpaz, Moshe; Wetzler, Meir.
In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 5, No. 5, 01.05.2007, p. 474-496.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Chronic myelogenous leukemia
AU - O'Brien, Susan
AU - Berman, Ellin
AU - Bhalla, Kapil
AU - Copelan, Edward A.
AU - DeVetten, Marcel P
AU - Emanuel, Peter D.
AU - Erba, Harry P.
AU - Greenberg, Peter L.
AU - Moore, Joseph O.
AU - Przepiorka, Donna
AU - Radich, Jerald P.
AU - Schilder, Russell J.
AU - Shami, Paul
AU - Smith, B. Douglas
AU - Snyder, David S.
AU - Soiffer, Robert J.
AU - Tallman, Martin S.
AU - Talpaz, Moshe
AU - Wetzler, Meir
PY - 2007/5/1
Y1 - 2007/5/1
N2 - Chronic myelogenous leukemia (CML) accounts for 15% of adult leukemias. In 2007, an estimated 4500 cases will be diagnosed and 900 patients will die of the disease. The goal of CML therapy is complete remission, which typically progresses from hematologic to cytogenetic remission. These updated 2007 guidelines include changes to several treatment recommendations, including considerations for imatinib dosing, the use of interferon, and management of dasatinib toxicity. Recommendations for hematopoetic stem cell transplantation have also been updated.
AB - Chronic myelogenous leukemia (CML) accounts for 15% of adult leukemias. In 2007, an estimated 4500 cases will be diagnosed and 900 patients will die of the disease. The goal of CML therapy is complete remission, which typically progresses from hematologic to cytogenetic remission. These updated 2007 guidelines include changes to several treatment recommendations, including considerations for imatinib dosing, the use of interferon, and management of dasatinib toxicity. Recommendations for hematopoetic stem cell transplantation have also been updated.
KW - Chronic myelogenous leukemia
KW - Desatinib
KW - Imatinib
KW - Karyotyping
KW - NCCN clinical practice guidelines
KW - Polymerase chain reaction
KW - Transplantation
UR - http://www.scopus.com/inward/record.url?scp=34249288276&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34249288276&partnerID=8YFLogxK
M3 - Review article
C2 - 17509252
AN - SCOPUS:34249288276
VL - 5
SP - 474
EP - 496
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
SN - 1540-1405
IS - 5
ER -